S&C Advises Biohaven in $11.6 Billion Acquisition by Pfizer

May 12, 2022

Pfizer has agreed to acquire Biohaven, the manufacturer of an anti-migraine technology called CGRP, in an $11.6 billion transaction. The transaction represents Pfizer's attempt to diversify beyond pandemic products and is Pfizer's deal largest since its $14 billion purchase of cancer drugmaker Medivation in 2016.
Biohaven Pharmaceutical Holding Co is the producer of Nurtec ODT, a migraine drug promoted by celebrity Khloe Kardashian, and has 6 other drugs in development.
The S&C team on the transaction includes Frank Aquila, Scott Crofton, Mimi Wu, Jeffrey MacDonald and Elizabeth Levin. Bob Downes is advising on securities matters. Davis Wang, John Jo, and Limeng Sun are advising on tax matters. Matthew Friestedt, Sarah Remmer Long and Rebekah Kostelak are advising on executive compensation matters. RuiHui Yu and Man Wing Elizabeth Cheung are advising on IP matters.